MoxDuo IR: Completed Phase III enrollment

QRxPharma completed enrollment of 140 patients in a U.S. Phase III trial (Study 009) of MoxDuo IR after a blinded interim analysis of 70 completed patients indicated that the enrollment would allow fo...